dexrazoxane has been researched along with Dermatitis Medicamentosa in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bize, P; Denys, A; Deplanque, G; Duran, R; Orcurto, A; Shabafrouz, K; Stalder, G | 1 |
| Aigner, B; Arzberger, EJ; Bauernhofer, T; Niederkorn, A; Petru, E; Richtig, E | 1 |
1 review(s) available for dexrazoxane and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexrazoxane; Dimethyl Sulfoxide; Drug Eruptions; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Free Radical Scavengers; Humans; Middle Aged; Time Factors; Topoisomerase II Inhibitors | 2014 |
1 other study(ies) available for dexrazoxane and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Dexrazoxane prevents skin necrosis in non-target embolization of falciform artery during transcatheter arterial chemoembolization (TACE).
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dermatologic Agents; Dexrazoxane; Drug Eruptions; Embolization, Therapeutic; Hepatic Artery; Humans; Liver Neoplasms; Male; Necrosis; Skin | 2018 |